Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery

Barrowcliffe, 1992 Kakkar, 1982, Low molecular weight heparin in the prophylaxis of venous thrombosis, BMJ, 284, 375, 10.1136/bmj.284.6313.375 Kakkar, 1986, Efficcy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: a co-operative study, Br J Surg, 71, 786 Kakkar, 1986, Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thromboembolism, Haemostasis, 16, 19 European Fraxiparin Study Group, 1988, Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery, Br J Surg, 75, 1058, 10.1002/bjs.1800751105 Leizorovicz, 1991, Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double-blind study comparing two doses of logiparin and standard heparin, Br J Surg, 78, 412, 10.1002/bjs.1800780410 Koller, 1986, Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery: a randomised, double-blind study versus unfractionated heparin, Thromb Haemost, 56, 243, 10.1055/s-0038-1661658 Sasahara, 1986, Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis, Br J Surg, 73, 697, 10.1002/bjs.1800730906 Salcuni, 1988, A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients, Curr Ther Res, 43, 824 Steiner, 1989, A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with Acenocoumarol) in patients undergoing gynaecological surgery, Arch Gynecol Obstet, 244, 141, 10.1007/BF00931291 Kakkar, 1989, Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis, Am J Surg, 157, 413, 10.1016/0002-9610(89)90589-8 Frydman, 1988, The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg, J Clin Pharmacol, 28, 608, 10.1002/j.1552-4604.1988.tb03184.x Briant, 1989, Unfractionated heparin and CY216. Pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa: effects of intravenous and subcutaneous injection in rabbits, Thromb Haemostas, 61, 348, 10.1055/s-0038-1646593 Bratt, 1986, Low molecular weight heparin (KABI 2165, fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers, Thromb Res, 42, 613, 10.1016/0049-3848(86)90340-3 Bara, 1988, Pharmacokinetics of low molecular weight heparins, Acta Chir Scand, 543, 65 de Swart, 1982, Kinetics of intravenously administered heparin in normal humans, Blood, 60, 1251, 10.1182/blood.V60.6.1251.1251 Carter, 1982, The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparins and heparin, Blood, 59, 1239, 10.1182/blood.V59.6.1239.1239 Esquivel, 1982, Comparison between commercial heparin, low molecular weight heparin and pentosan polysulphate on haemostasis and platelets in vivo, Thromb Res, 28, 389, 10.1016/0049-3848(82)90120-7 Huber, 1992, Postoperative pulmonary embolism after hospital discharge: an underestimated risk, Arch surg, 127, 310, 10.1001/archsurg.1992.01420030076014 Clarke-Pearson, 1984, The natural history of postoperative venous thromboemboli in gynaecological oncology: a prospective study of 382 patients, Am J Obster Gynaecol, 148, 1051, 10.1016/0002-9378(84)90632-X 1975, Lancet, ii, 45 Kakkar VV, Boneu B, et al. Results of an International randomized double-blind trial comparing a new low molecular weight heparin (LU47311-Clivarine) with unfractionated heparin in the prevention of deep vein thrombosis after major abdominal surgery and a meta-analysis of previous studies (unpublished). Barzu, 1984, Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture, Nouv Rev Fr Hematol, 26, 243 Lane, 1986, Neutralizaton of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4, J Biol Chem, 261, 3980, 10.1016/S0021-9258(17)35610-7 Sobel, 1991, Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo, J Clin Invest, 87, 1787, 10.1172/JCI115198 Nurmohamed, 1992, The efficacy and safety of low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis, Lancet, 340, 152, 10.1016/0140-6736(92)93223-A Verstrate, 1990, Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins, Drugs, 40, 430 Jordan, 1980, The kinetics of haemostatic enzyme—antithrombin interactions in the presence of low molecular weight heparin, J Biol Chem, 255, 10081, 10.1016/S0021-9258(19)70431-1 Bradbrook, 1987, A low molecular weight heparinoid anticoagulant with a long half-life in man, Br J Pharmacol, 23, 667, 10.1111/j.1365-2125.1987.tb03100.x Bazu, 1985, Binding and endocytosis of heparin by human endothelial cells in culture, Biochem Biophys Acta, 845, 196, 10.1016/0167-4889(85)90177-6 1990 Salzman, 1980, Prophylaxis of venous thrombo-embolism: analysis of cost effectiveness, Ann Surg, 191, 207, 10.1097/00000658-198002000-00013 Bergqvist, 1988, The economics of general thromboembolic prophylaxis, World J Surg, 12, 349, 10.1007/BF01655669